Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Product G Clear all
Completed Phase 2Phase 3 Interventional Results available

Vaginal Estriol in Multiple Sclerosis

NCT03774407
View directory record Official record
Conditions
Multiple Sclerosis, Neurogenic Bladder
Interventions
vaginal estriol
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection

NCT00000663
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 5 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 4 Interventional

Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life

NCT00147914
View directory record Official record
Conditions
Acute Bacterial Sinusitis
Interventions
Cefdinir (drug), amoxicillin/clavulanate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 24, 2026, 8:44 AM EDT
Recruiting Not applicable Interventional

BLOOM: Pragmatic Feasibility Trial

NCT07287332
View directory record Official record
Conditions
Sepsis, Infection
Interventions
Up-front individualized dosing algorithm, Usual Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 24, 2026, 8:44 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Platelet Rich Plasma Injections In Young And Old Human Subjects

NCT06451120
View directory record Official record
Conditions
Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions
Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

NCT03166215
View directory record Official record
Conditions
Developmental and/or Epileptic Encephalopathies
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Port Charlotte, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 4 Interventional

Benefit of Elevation of HDL-C in Women

NCT01921010
View directory record Official record
Conditions
Cardiovascular Outcomes
Interventions
Niaspan, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 24, 2026, 8:44 AM EDT
Terminated Phase 2 Interventional Results available

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

NCT05785390
View directory record Official record
Conditions
COVID-19
Interventions
NP-101, Placebo
Drug · Other
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Miami, Florida • Berwyn, Illinois • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 1 Interventional

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

NCT02740985
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions
AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 3 Interventional Results available

High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma

NCT00354744
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy, filgrastim
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 118 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 2 Interventional Results available

Urinary Track Infection Prevention After Urogynecological Surgery

NCT03818321
View directory record Official record
Conditions
Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
Interventions
Methenamine Hippurate 1 g tablet, Placebo tablet
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

NCT02876796
View directory record Official record
Conditions
PD Effects of GS-0976 (NDI-010976) on Fractional DNL
Interventions
GS-0976, Placebo, 1-13C acetate, Fructose solution
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 2 Interventional

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

NCT00003203
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Neuroblastoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, vincristine sulfate, adjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
35
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resveratrol and Midazolam Metabolism

NCT01173640
View directory record Official record
Conditions
Healthy
Interventions
Midazolam, resveratrol (single dose), resveratrol (multiple dose)
Drug · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Sep 24, 2026, 8:44 AM EDT
Terminated Phase 4 Interventional Results available

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

NCT04673175
View directory record Official record
Conditions
Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
Ceftolozane / Tazobactam Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 24, 2026, 8:44 AM EDT
Terminated Phase 1 Interventional Results available

Hematopoietic Stem Cell Support in Vasculitis

NCT00278512
View directory record Official record
Conditions
Vasculitis
Interventions
Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant, Cyclophosphamide, ATG (rabbit), G-CSF, Campath-1h, Fludarabine, Tacrolimus, Mesna
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Not applicable Interventional Results available

Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders

NCT03093844
View directory record Official record
Conditions
Hematologic Disorders
Interventions
Miltenyi CliniMACS® CD34 Reagent System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of an Arabinogalactan Product

NCT04005924
View directory record Official record
Conditions
Postprandial Blood Glucose
Interventions
arabinogalactan
Other
Lead sponsor
Biofortis, Merieux NutriSciences
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days

NCT00616018
View directory record Official record
Conditions
Drug Induced Liver Injury
Interventions
acetaminophen
Drug
Lead sponsor
Kennon Heard
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Sep 24, 2026, 8:44 AM EDT
Recruiting No phase listed Observational

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

NCT06274788
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Interventions
Omegaven® (fish oil triglycerides) Injectable Emulsion
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
1 Day to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Fountain Valley, California • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 2 Interventional

Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

NCT06935838
View directory record Official record
Conditions
Obesity and Overweight, HIV, Chronic Inflammation
Interventions
Tirzepatide
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn

NCT05363618
View directory record Official record
Conditions
Heartburn
Interventions
Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml), Placebo 1.4 ml
Dietary Supplement · Other
Lead sponsor
Microbiome Health Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 3 Interventional

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

NCT00000935
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Transplantation
Interventions
Intravenous immune globulin (IVIG)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 24, 2026, 8:44 AM EDT
Completed Phase 4 Interventional Results available

Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)

NCT04811339
View directory record Official record
Conditions
Diarrhea, COVID-19
Interventions
Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable, Placebo oral tablet without BSS
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 24, 2026, 8:44 AM EDT